SAN DIEGO, June 12, 2025 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ: DARE), a biopharmaceutical company driven by a mission to challenge the status quo, making women's health a priority, today announced that the company’s 2025 annual meeting of stockholders (the “Annual Meeting”) was convened and adjourned without any business conducted due to lack of the required quorum. A quorum is necessary to hold the Annual Meeting. There were fewer than a majority of shares entitled to vote present, either in p ...

Rosy Wellness is a multi-award winning app recommended by 8,000+ healthcare professionals Daré expects to start recording revenue in the 4th quarter this year Collaboration will leverage Rosy Wellness' extensive reach and community of over 250,000 women For more information, please visit www.darebioscience.com and www.meetrosy.com. About Rosy Wellness SAN DIEGO, June 04, 2025 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ: DARE), a biopharmaceutical company driven by a mission to challenge the status quo ...

Dare Bioscience, Inc. (DARE) came out with a quarterly loss of $0.50 per share versus the Zacks Consensus Estimate of a loss of $0.63. This compares to loss of $0.84 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of 20.63%. A quarter ago, it was expected that this company would post a loss of $0.66 per share when it actually produced a loss of $0.64, delivering a surprise of 3.03%.Over the last four quarters, the company has sur ...

Daré Bioscience (DARE) Q1 2025 Earnings Call May 13, 2025 04:30 PM ET Company Participants MarDee Haring-Layton - Chief Accounting OfficerSabrina Johnson - President, CEO & DirectorDouglas Tsao - Managing DirectorLeona Nease - Biotech Equity Research AssociateWill Hidell - Equity Research Associate Operator Welcome to the conference call hosted by Dare Bioscience to review the company's First Quarter twenty twenty five Financial Results and to provide a business update. This call is being recorded. My name ...

Daré Bioscience (DARE) Q1 2025 Earnings Call May 13, 2025 04:30 PM ET Speaker0 Welcome to the conference call hosted by Dare Bioscience to review the company's First Quarter twenty twenty five Financial Results and to provide a business update. This call is being recorded. My name is Gail, and I will be your operator today. With us today from Dare are Sabrina Martucci Johnson, President and Chief Executive Officer and Marty Harrington, chief accounting officer. Ms. Harrington, please proceed. Speaker1 Good ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-36395 DARÉ BIOSCIENCE, INC. (Exact Name of Registrant as Specified in its Charter) Delaware (State or Other Jurisdiction of Incor ...

● Four on-market products will accelerate revenue generation and provide path to profitability Exhibit 99.1 Daré Bioscience Reports First Quarter 2025 Financial Results and Provides Company Update In addition to its proprietary Sildenafil Cream formulation, Daré is taking action to make three other solutions for women available commercially, two vaginal probiotics in 2025 and its proprietary monthly hormone therapy in 2026 ● Creates commercial opportunity in the estimated up to $4.5 billion compounded hormo ...

Creates commercial opportunity in the estimated up to $4.5 billion compounded hormone therapy market, enabling women to access an evidence-based solutionFour on-market products will accelerate revenue generation and provide path to profitabilityDaré expects to start recording revenue in the 4th quarter of this year Conference call today at 4:30 p.m. ET to discuss the further expanded business strategy to commercialize multiple solutions in 2025 and 2026 2025 and 2026 Milestones Sildenafil Cream, 3.6% an inv ...

文章核心观点 公司总裁兼首席执行官将在会议上介绍公司扩展业务战略，采用双路径方法将专有配方推向市场，今年先推出专有西地那非乳膏配方，还可能推出非处方消费健康产品 [1][2] 公司业务战略 - 采用双路径方法，将503B复合作为一部分，尽快将部分专有配方推向市场，今年先推出专有西地那非乳膏配方 [1] - 积极评估其他专有配方的双路径方法，还可能推出无需医生处方的消费健康产品，目标本季度提供时间和战略合作伙伴的最新情况 [2] 会议信息 - 会议名称为琼斯医疗保健与技术创新会议 [3] - 时间为2025年4月9日星期三下午1点（太平洋时间） [3] - 网络直播链接为https://wsw.com/webcast/jones2/dare/1859132 ，演示回放将在公司网站投资者板块“演示、活动与网络直播”下提供至2025年4月23日 [3] 公司简介 - 是一家生物制药公司，使命是挑战现状，将女性健康作为优先事项，目标是尽快推出创新的循证解决方案，满足女性健康未满足的需求 [4] - 首款FDA批准的产品是XACIATO™（磷酸克林霉素）阴道凝胶2%，用于治疗12岁及以上女性细菌性阴道病，与欧加农有全球许可协议 [5] - 产品组合还包括处于临床开发阶段的潜在同类首创候选产品，如Ovaprene®、3.6%西地那非乳膏、DARE - HRT1等 [5] 公司荣誉 - 公司领导层入选《制药商》权力榜和《端点新闻》生物制药女性榜单，首席执行官被评为《激烈制药》生物制药最有影响力人物之一 [6] 产品时间规划 - 应医疗界呼吁并听取女性需求后，推出专有西地那非乳膏配方双路径方法，目标2025年第四季度通过处方提供该配方 [7] 信息发布渠道 - 公司可能通过网站投资者板块、SEC文件、新闻稿、公开电话会议和网络直播等渠道发布重要信息，也可能使用社交媒体，鼓励投资者等关注 [8]

财务表现 - 季度每股亏损0.64美元 低于Zacks共识预期的0.66美元亏损 较去年同期0.72美元亏损有所改善 [1] - 季度营收出现负值-0.06百万美元 远低于Zacks共识预期 偏差达101.6% 去年同期营收为1.81百万美元 [2] - 过去四个季度中 三次超过每股收益预期 但均未达到营收预期 [2] 市场反应 - 年初至今股价下跌7.7% 表现逊于标普500指数5.1%的跌幅 [3] - 当前Zacks评级为3级(持有) 预计短期内表现与市场持平 [6] 未来展望 - 下季度共识预期为每股亏损0.65美元 营收0.6百万美元 本财年预期亏损1.90美元 营收9.81百万美元 [7] - 收益预期修订趋势呈现混合状态 后续可能随财报发布调整 [6] 行业比较 - 所属医疗生物技术与遗传学行业在Zacks行业排名中位列前27% 前50%行业平均表现是后50%的两倍以上 [8] - 同业公司Lifecore Biomedical预计下季度每股亏损0.14美元 同比恶化180% 营收预期36.6百万美元 同比增长2.5% [9][10]